AVRO News and Press, AVROBIO Inc. From 10/05/20

Investigational gene therapy licensed from The University of Manchester, UK aims to address both physical and CNS manifestations of Hunter syndrome Expands leading pipeline targeting lysosomal disorders with 5 th investigational gene therapy Program expected to ent...

Strong need for improved enzyme replacement therapies. Protalix's deliberately engineered ERT appears to fill this unmet need. Significant potential for share price appreciation. For further details see: Protalix Could Claim Substantial Global Market Share In Fabry Disea...

Avrobio' (AVRO) AVR-RD-02, a gene therapy for the treatment of Gaucher disease, has been granted Orphan Drug status by the European Commission.AVR-RD-02 consists of patient’s genetically modified hematopoietic stem cells, to express glucocerebrosidase (GCase), ...

AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the European Commission (EC) has granted orphan drug designation for AVR-RD-02, the company’s investigational ge...

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Economic reports in the week aheadA relatively light earnings and conference calendar in the week ahead doesn't mean a break for investors. The U.S. airlin...

AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that members of its senior management team are scheduled to participate in two upcoming virtual investor conferences. ...

Youdao (DAO), Avrobio (AVRO), Merus (MRUS), and PrimeEnergy (PNRG) are four stocks recently downgraded by the POWR Ratings. If the market decline resumes, it's likely that these stocks will lead to the downside. The latest POWR Ratings  have arrived. A wide array of stocks w...

The following slide deck was published by AVROBIO, Inc. in conjunction with this Read more ...

AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that members of its senior management team are scheduled to participate in three upcoming virtual investor conferences. Citi...

The following slide deck was published by AVROBIO, Inc. in conjunction with this Read more ...